文献速递临床生化临床免疫质量管理与危急值

Alan H.B. Wu教授:经得起时间检验的贡献

Professor Alan H.B. Wu: Contributions that will stand the test of time.
PubMed 文献 · Clin Chim Acta · 2025-12-18

本文致敬Alan H.B. Wu博士担任Clinica Chimica Acta主编25年的领导工作及其对临床化学和实验室医学的变革性贡献。其核心贡献在于推进心脏生物标志物(尤其是心肌肌钙蛋白和利钠肽)用于心肌梗死和心力衰竭的诊疗,并推动个体化检验医学解读。

要点

  • 推动心肌肌钙蛋白诊断与预后价值确立及高敏检测方法发展
  • 强调生物学变异对群体参考区间的限制,倡导个体化结果解读
  • 通过指南与协作影响生物标志物采纳和实验室质量标准

核心结论

  • Wu教授在心脏生物标志物、检测标准化和个体化检验医学方面的贡献持续推动诊断进步与患者照护改善。

主要发现

  • 其研究帮助确立了心肌肌钙蛋白的诊断与预后价值,并促进标准化和高敏检测方法的发展。
  • 关于生物学变异的工作强调了基于群体的参考区间的局限性,并推动检验结果的个体化解读。

临床怎么用

  • 临床可借鉴其推动心肌肌钙蛋白和利钠肽用于心肌梗死与心力衰竭诊疗的理念。
  • 检验结果解读应关注个体化,而非仅依赖群体参考区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article honors Dr. Alan H.B. Wu's 25-year leadership as Editor-in-Chief of Clinica Chimica Acta and his transformative contributions to clinical chemistry and laboratory medicine. A central focus of his career has been advancing the use of cardiac biomarkers, particularly cardiac troponin (cTn) and natriuretic peptides, for the diagnosis and management of myocardial infarction and heart failure. Dr. Wu's studies helped establish the diagnostic and prognostic value of cTn, contributed to standardization and high-sensitivity assay development, and explored novel technologies. His work on biological variability emphasized the limitations of population-based reference intervals and promoted individualized interpretation of test results. Through guidelines and collaborations, Dr. Wu has shaped biomarker adoption, clinical practice, and laboratory quality standards. His vision of personalized laboratory medicine continues to advance diagnostics and improve patient care.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Christenson RH, Kavsak P, van Wijk XMR, et al. Professor Alan H.B. Wu: Contributions that will stand the test of time. Clin Chim Acta. 2025. PMID: 41421759. doi:10.1016/j.cca.2025.120795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。